TD Private Client Wealth LLC Has $119,000 Position in ICON Public Limited (NASDAQ:ICLR)

TD Private Client Wealth LLC lowered its holdings in ICON Public Limited (NASDAQ:ICLR) by 83.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 568 shares of the medical research company’s stock after selling 2,842 shares during the period. TD Private Client Wealth LLC’s holdings in ICON Public were worth $119,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sierra Ocean LLC acquired a new position in ICON Public during the fourth quarter valued at $29,000. Park Place Capital Corp grew its stake in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares in the last quarter. Private Trust Co. NA increased its holdings in shares of ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 82 shares during the period. GAMMA Investing LLC lifted its position in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares in the last quarter. Finally, Horizon Investments LLC boosted its holdings in shares of ICON Public by 534.0% during the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock worth $137,000 after purchasing an additional 550 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ICLR. JPMorgan Chase & Co. dropped their price objective on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. William Blair reiterated an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Robert W. Baird lowered their target price on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Truist Financial dropped their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Barclays reduced their price target on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $272.50.

ICON Public Stock Down 2.9 %

ICLR opened at $179.02 on Wednesday. ICON Public Limited has a twelve month low of $174.93 and a twelve month high of $347.72. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The business has a 50 day moving average price of $191.67 and a 200 day moving average price of $223.96. The firm has a market cap of $14.46 billion, a P/E ratio of 18.78, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. Research analysts forecast that ICON Public Limited will post 13.38 EPS for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.